Relapsed or Refractory Acute Myeloid Leukemia (AML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Relapsed or Refractory Acute Myeloid Leukemia (AML) Market Outlook
Thelansis’s “Relapsed or Refractory
Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2024 To 2034" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Relapsed
or Refractory Acute Myeloid Leukemia (AML) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Relapsed or Refractory Acute Myeloid
Leukemia (AML) Overview
Acute
myeloid leukemia (AML) is characterized by the uncontrolled growth of
undifferentiated myeloid stem cells, accumulating immature myeloblasts. The
standard approach to induce remission in AML has been a chemotherapy regimen
combining cytarabine and anthracycline (commonly called “7+3”) for thirty
years. However, relapse and refractory disease persist despite its
long-standing use, with a median overall survival of under 6 months. Several
factors have been linked to worse outcomes, including age exceeding 65 years,
unfavorable cytogenetics, and a first complete remission lasting less than 12
months. The treatment of relapsed or refractory AML presents low remission
rates following initial salvage therapy, and these rates decline further with
subsequent treatment attempts. The sole curative option for relapsed or
refractory AML patients is a hematopoietic stem cell transplant, but its high
mortality risk renders it unsuitable for many patients.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment